View Older Stories View More Recent Stories
-
Bluebird Bio (BLUE) Price Target Raised to $120 at Roth
-
Roth Positive on Spectrum Pharma (SPPI) Following CE-Melphalan NDA Filing (LGND)
-
Roth 'Encouraged' by Progress, Biz Development of BioLineRx's (BLRX) BL-5010; Affirms 'Buy' Rating
-
Keryx Biopharma's (KERX) U.S. Launch of AURYXIA Follows Robust Development Program; Roth Affirms 'Buy' Rating
-
Roth Affirms Cytokinetics (CYTK) at 'Buy'; Astellas Collaboration Development is Encouraging
-
Roth Capital Starts Energous Corp (WATT) at Buy
-
Roth Comments on Ligand Pharma (LGND) Following EU Marketing Authorization of Duavive
-
Roth Affirms Cytori Therapeutics (CYTX) at 'Buy'; BARDA Affirms Strong Support for Thermal Burn Cell Therapy
-
LED Lamp sales at Staples.com Will be 'Incremental Positive' for Revolution Lighting (RVLT) - Roth Capital
-
Roth Capital 'Favorable' on Curis' (CRIS) CUDC-907 Following Phase 1 Initiation in a/r Solid Tumors
-
Roth Capital Downgrades Volcano Corp. (VOLC) to Neutral
-
MEI Pharma (MEIP) Completes 10M Common Offering
-
New DoC Antidumping Tariffs Worse-than-Expected for Most Chinese Producers - Roth (TSL) (JASO) (SCTY)
-
Roth Capital Starts Barracuda Networks (CUDA) at Buy
-
Roth Capital Still Positive on Celldex (CLDX) Upon Completion of Phase III ACT IV Enrollment
-
bluebird bio (BLUE) Reports $150M Stock Offering
-
Roth Capital Lifts PT on BioLineRx (BLRX) to $10.50 Following Investor Day; BL-8040 in AML Remains Promising
-
Roth Capital Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Buy
-
Roth Keeps BioLineRx (BLRX) at 'Buy'; Sees BL-8040 Plan Progressing Nicely Following Recent Update
-
Notable 52-Week Highs and Lows 12/12: (ADBE) (MACK) (BLUE) High; (EOX) (RSH) (MCP) Low
-
Roth Affirms Synta Pharma (SNTA) at 'Buy'; Early Ganetespib Data is 'Encouraging'
-
Roth Remains Positive on Canadian Solar (CSIQ) Following Investor Meetings; Maintains 'Buy' Rating
-
MEI Pharma (MEIP) Prices 10M Share Offering at $4/Share
-
Roth Afirms Peregrine Pharma (PPHM) at Buy Following Q2 Numbers; Looking to Data-Heavy 2015
-
Roth Boosts PT on TG Therapeutics (TGTX) to $33 on Strong ASH Showing, Buyout Prospects
-
Pre-Open Stock Movers 12/10: (SNSS) (RVLT) (COST) Higher; (GDP) (ALLT) (YUM) Lower (more...)
-
Energous (WATT) 2.86M Offering Prices at $7/Share
-
Roth Remains Cautious on Sunesis Pharma (SNSS) Pending FDA Visibility on VALOR
-
Roth Capital Starts Energy Focus (EFOI) at Buy
-
Roth Capital Starts Revolution Lighting Technologies (RVLT) at Buy
-
Pharmacyclics (PCYC) Impresses at ASH; KOLs Excited About Prospects for Imbruvica - Roth Capital
-
Roth Capital Starts Neuroderm Ltd (NDRM) at Buy
-
Roth Capital Starts The Joint Corp (JYNT) at Buy
-
Galena's (GALE) GALE-401 More Promising Following Presentation Phase 2 Data at ASH - Roth
-
Roth 'Encouraged' by Early Signs of BL-8040 Activity in AML; Affirms BioLineRx at 'Buy'
-
TG Therapeutics's (TGTX) TGR-1202 Keeps Getting Better; Roth Affirms 'Focus Pick' Rating
-
Roth Capital Starts Sky Solar (SKYS) at Buy
-
Roth Capital Downgrades LeapFrog (LF) to Neutral
-
Roth Comments on Celldex (CLDX) Following Initiation of CDX-011 Phase II
-
Roth Affirms Cytori (CYTX) at 'Buy'; Celution, ADRCs 'de-Risked' in Japan on New Regulatory Measures
-
Roth Capital Starts Renewable Energy Group (REGI) at Buy
-
Roth Capital Starts FutureFuel Corp. (FF) at Buy
-
Roth Capital Starts RSP Permian, Inc. (RSPP) at Buy
-
Roth Capital Starts Ring Energy, Inc. (REI) at Buy
-
Roth Capital Starts Clayton Williams Energy (CWEI) at Buy
-
Roth Capital Starts Callon Petroleum (CPE) at Buy
-
Regeneron's (REGN) Eylea sBLA Receives Priority Review as DME + Diabetic Retinopathy Treatment; Roth Capital Comments
-
TG Therapeutics (TGTX) Still 'Focus Pick' at Roth; New Phase 1/1b of TGR-1202 + Imbruvica Announced
-
Roth Affirms Can-Fite BioPharma (CANF) at 'Buy' Following Q3 Results; Still Sees FY15 as 'Breakout' Year
-
Roth Capital Starts Dynamic Materials (BOOM) at Buy

